Interleukin-8 Concentration in Peritoneal Fluid of Patients with Endometriosis and Modulation of Interleukin-8 Expression in Human Mesothelial Cells
Overview
Reproductive Medicine
Authors
Affiliations
Interleukin-8 (IL-8) is a chemoattractant and activating factor for human neutrophlls and a potent angiogenic agent. The peritoneal fluid of women with endometriosis has been shown to have increased neutrophil chemotactic activity. We postulate that IL-8 may be an important modulator in the pathogenesis of endometriosis and adhesion formation. We first investigated IL-8 concentrations in the peritoneal fluid of women with or without endometriosis, then assessed peritoneal mesothelial cells as a potential source of peritoneal fluid IL-8. Northern blot analysis and enzyme-linked immunosorbent assay (ELISA) were used to investigate IL-8 mRNA and protein modulation. The mean concentration of IL-8 in samples obtained from control patients (n = 28) was 4.8 +/- 0.5 pg/ml; from patients with minimal-mild endometriosis (n = 24) was 27.5 +/- 2.6 pg/ml; and from patients with moderate-severe endometriosis (n = 21) was 530.2 +/- 65.1 pg/ml. Confluent mesothelial cells were incubated with human recombinant IL-1 alpha (0.01-100 IU/ml) or tumour necrosis factor (TNF)-alpha (0.01 to 100 ng/ml) for 2-24 h. IL-8 mRNA was detectable in non-treated cells, however both IL-1 alpha and TNF-alpha induced higher amounts of IL-8 mRNA in a dose- and time-dependent manner. Non-treated mesothelial cells in culture also produced and secreted IL-8 protein quantified by ELISA, but again higher concentrations were induced by IL-1 alpha and TNF-alpha treatment. In conclusion, we found that IL-8 concentrations were elevated in peritoneal fluids from women with endometriosis. Cultured mesothelial cells expressed cytokine-inducible IL-8 mRNA and secreted IL-8 protein. The regulated expression of this angiogenic factor may play a role in pathogenesis of endometriosis.
Jiang T, Chen Y, Gu X, Miao M, Hu D, Zhou H Int J Womens Health. 2023; 15:741-763.
PMID: 37200624 PMC: 10187648. DOI: 10.2147/IJWH.S404660.
Chen S, Chai X, Wu X BMC Genom Data. 2022; 23(1):20.
PMID: 35303800 PMC: 8932180. DOI: 10.1186/s12863-022-01036-y.
PPARγ Agonists: Emergent Therapy in Endometriosis.
Vallee A, Vallee J, Le Blanche A, Lecarpentier Y Pharmaceuticals (Basel). 2021; 14(6).
PMID: 34204039 PMC: 8229142. DOI: 10.3390/ph14060543.
Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.
AlAshqar A, Reschke L, Kirschen G, Borahay M Biol Reprod. 2021; 105(1):7-31.
PMID: 33739368 PMC: 8256101. DOI: 10.1093/biolre/ioab054.
Selection of New Probiotics for Endometrial Health.
Chenoll E, Moreno I, Sanchez M, Garcia-Grau I, Silva A, Gonzalez-Monfort M Front Cell Infect Microbiol. 2019; 9:114.
PMID: 31058101 PMC: 6481279. DOI: 10.3389/fcimb.2019.00114.